Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

ARIA: Real-world Utilization and Outcomes With Dacomitinib First-line Treatment for EGFR Mutation-positive Advanced Non-small Cell Lung Cancer Among Asian Patients - A Multi-center Chart Review

NCT04609319 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT04609319
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04609319 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
ARIA: Real-world Utilization and Outcomes With Dacomitinib First-line Treatment for EGFR Mutation-positive Advanced Non-small Cell Lung Cancer Among Asian Patients - A Multi-center Chart Review
Lead sponsor
Pfizer
Phase
Observational
Overall status
Completed
Start date
June 11, 2021
Completion date
May 28, 2024
Enrollment
307 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

lung cancer